BRIEF-Evogene Announces Successful Completion Of Phase 1 Clinical Study Of Bmc128, A Rationally Designed Live Bacterial Product, In Combination With Nivolumab By Its Subsidiary Biomica

Evogene Ltd

Evogene Ltd

EVGN

0.00

June 2 (Reuters) - Evogene Ltd EVGN.TA:

  • EVOGENE ANNOUNCES SUCCESSFUL COMPLETION OF PHASE 1 CLINICAL STUDY OF BMC128, A RATIONALLY DESIGNED LIVE BACTERIAL PRODUCT, IN COMBINATION WITH NIVOLUMAB BY ITS SUBSIDIARY BIOMICA

  • EVOGENE - STUDY MET PRIMARY ENDPOINT WITH FAVORABLE SAFETY, NO DOSE-LIMITING TOXICITIES

  • EVOGENE LTD: STUDY RESULTS DEMONSTRATED FAVORABLE SAFETY PROFILE AND PRELIMINARY SIGNALS OF CLINICAL ACTIVITY

Source text: ID:nPnbyG1xpa

Further company coverage: EVGN.TA


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.